MX2023013272A - Agentes para tecnicas de conjugacion dirigida y productos conjugados. - Google Patents

Agentes para tecnicas de conjugacion dirigida y productos conjugados.

Info

Publication number
MX2023013272A
MX2023013272A MX2023013272A MX2023013272A MX2023013272A MX 2023013272 A MX2023013272 A MX 2023013272A MX 2023013272 A MX2023013272 A MX 2023013272A MX 2023013272 A MX2023013272 A MX 2023013272A MX 2023013272 A MX2023013272 A MX 2023013272A
Authority
MX
Mexico
Prior art keywords
agents
conjugation techniques
directed conjugation
conjugated products
present disclosure
Prior art date
Application number
MX2023013272A
Other languages
English (en)
Spanish (es)
Inventor
Gene M Dubowchik
David Adam Spiegel
Wieslaw Kazmierski
Reese M Caldwell
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2023013272A publication Critical patent/MX2023013272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013272A 2021-05-17 2022-05-17 Agentes para tecnicas de conjugacion dirigida y productos conjugados. MX2023013272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163189522P 2021-05-17 2021-05-17
PCT/US2022/029535 WO2022245759A2 (en) 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products

Publications (1)

Publication Number Publication Date
MX2023013272A true MX2023013272A (es) 2023-11-30

Family

ID=84140970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013272A MX2023013272A (es) 2021-05-17 2022-05-17 Agentes para tecnicas de conjugacion dirigida y productos conjugados.

Country Status (11)

Country Link
US (1) US20240252674A1 (https=)
EP (1) EP4340891A4 (https=)
JP (1) JP2024519814A (https=)
KR (1) KR20240012380A (https=)
CN (1) CN117750979A (https=)
AU (1) AU2022275832A1 (https=)
CA (1) CA3219517A1 (https=)
IL (1) IL307799A (https=)
MX (1) MX2023013272A (https=)
PH (1) PH12023553154A1 (https=)
WO (1) WO2022245759A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219475A1 (en) * 2021-05-17 2022-11-24 Wieslaw Kazmierski Compositions including conjugated therapy enhancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
PL3086814T3 (pl) * 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
WO2017042944A1 (ja) * 2015-09-10 2017-03-16 国立大学法人山梨大学 フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
EP3617235B1 (en) * 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
MX421628B (es) * 2017-07-26 2025-03-14 Kleo Pharmaceuticals Inc Compuestos abt universales y usos de los mismos
JP7404230B2 (ja) * 2017-09-18 2023-12-25 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
AU2020299157A1 (en) * 2019-07-03 2022-01-20 Kleo Pharmaceuticals, Inc. CD38-binding agents and uses thereof

Also Published As

Publication number Publication date
WO2022245759A3 (en) 2023-02-02
KR20240012380A (ko) 2024-01-29
AU2022275832A1 (en) 2023-12-14
US20240252674A1 (en) 2024-08-01
CN117750979A (zh) 2024-03-22
WO2022245759A2 (en) 2022-11-24
CA3219517A1 (en) 2022-11-24
IL307799A (en) 2023-12-01
PH12023553154A1 (en) 2024-03-11
JP2024519814A (ja) 2024-05-21
EP4340891A4 (en) 2025-07-02
EP4340891A2 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
PH12022551000A1 (en) Directed conjugation technologies
MX2022011825A (es) Conjugados neodegradadores.
MX2023008339A (es) Conjugados anticuerpo-fármaco de camptotecina y métodos de uso de estos.
ZA201903667B (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
PA8626201A1 (es) Conjugados de caliqueamicina
NZ739788A (en) Phthalocyanine dye conjugates and their storage
CL2012000980A1 (es) Inmunoglobulina de dominio variable dual que comprende una cadena de polipeptidos con dos dominios variables que se unen a cd3 y a cd19 y; conjugado con la proteina de union; celula huesped, vector y acido nucleico, metodo de produccion, composicion, metodo in vitro que utiliza la proteina y usos para preparar un medicamento.
NZ712035A (en) Pyrrolobenzodiazepines and conjugates thereof
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
WO2023250391A3 (en) Compositions and methods comprising antibodies that bind to covalent peptide conjugates
MX2023010099A (es) Enlazadores ramificados para conjugados de anticuerpo-fármaco y métodos de uso de estos.
MX2022000815A (es) Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia.
MX2025000590A (es) Anticuerpo anti-trop2 y conjugados del mismo
MX2025002569A (es) Anticuerpos anti-trop2/egfr y usos de estos
IN2012DN01662A (https=)
AU2021397796A9 (en) Immunoconjugates comprising an anti-cea antibody linked by conjugation to one or|more 8-het-2- aminobenzazepine derivatives useful in treating cancer
PH12023553153A1 (en) Antibody drug conjugates using mates technology for delivering cytotoxic agents
WO2022183112A3 (en) Compositions and methods comprising antibodies that bind to covalent peptide conjugates
PH12023553154A1 (en) Agents for directed conjugation techniques and conjugated products
WO2021003050A3 (en) Cd38-binding agents and uses thereof
MX2024013871A (es) Agentes aglutinantes 5t4 y usos de los mismos
ZA202100761B (en) Improvements in immunogenic conjugates
MX2025002614A (es) Conjugados de farmaco-anticuerpo contra el factor tisular y usos de estos
MX2025004585A (es) Anticuerpos, conjugados anticuerpo-farmaco, preparaciones y usos de los mismos
WO2022020473A3 (en) Disruption of cd28-sialoside ligand complexes to enhance t cell activation